The Market Herald: Resverlogix (TSX:RVX) steps up Phase 2b study for COVID-19 treatment


Resverlogix (RVX) has initiated the first Brazilian and a second Canadian site for its Phase 2b clinical trial for COVID-19 treatment. The study aims to evaluate the safety and efficacy of Canadian-developed apabetalone as a potential oral treatment for COVID-19. Donald J. McCaffrey, President & CEO of Resverlogix sat down with Shoran Devi to discuss the study.


For the full interview with Donald McCaffrey

and to learn more about Resverlogix's study, click here.


SOURCE



Recent Posts

See All